Trials / Unknown
UnknownNCT04198480
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
A Phase I/II, Single Arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory Hypercalcemia of Malignancy
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- Sponsor
- Shanghai JMT-Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.
Detailed description
This is a Phase I/II, Single arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With refractory Hypercalcemia of Malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JMT103 | 2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15. |
Timeline
- Start date
- 2020-01-24
- Primary completion
- 2021-07-30
- Completion
- 2021-12-31
- First posted
- 2019-12-13
- Last updated
- 2019-12-13
Source: ClinicalTrials.gov record NCT04198480. Inclusion in this directory is not an endorsement.